Related Experiment Video
Updated: Jun 11, 2026
06:13
Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses
Published on: November 24, 2014
A fully replication-competent adenovirus vector with enhanced oncolytic properties.
K Toth1, M Kuppuswamy, E V Shashkova
1Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St Louis, MO 63104, USA.
Cancer Gene Therapy
|July 3, 2010
Summary
INGN 007, an oncolytic adenovirus vector, demonstrated superior tumor suppression and increased survival in preclinical models. This engineered adenovirus shows promise for enhanced clinical efficacy against various cancers.
Area of Science:
- Oncolytic virotherapy
- Gene therapy
- Cancer research
Background:
- Adenovirus vectors are utilized for cancer treatment.
- Modifications to adenovirus genes, such as E1A, can alter their oncolytic properties.
- Overexpression of the Adenovirus Death Protein (ADP) is a strategy to enhance cell lysis.
Purpose of the Study:
- To compare the oncolytic efficacy of two adenovirus vectors, KD3 and INGN 007, with distinct E1A gene modifications.
- To evaluate the antitumor activity of these vectors in various preclinical cancer models.
- To assess the potential of INGN 007 as a superior oncolytic agent compared to existing therapies.
Main Methods:
- Development of two adenovirus vectors: KD3 (E1A deletions) and INGN 007 (wild-type E1A), both overexpressing ADP.
- Administration of vectors via intratumoral and intravenous injection in mouse models bearing human tumors (A549, Hep3B, LNCaP).
- Evaluation of tumor growth suppression, tumor shrinkage/disappearance, and survival rates.
- Comparison of INGN 007 efficacy against wild-type Ad5 and dl1520 (ONYX-015).
Main Results:
- Both KD3 and INGN 007 suppressed subcutaneous tumor growth in A549 and Hep3B models after intratumoral injection.
- Intravenous injection of KD3 and INGN 007 contained LNCaP tumor growth, with some tumors shrinking or disappearing.
- INGN 007 significantly increased mean survival time (35%) against subcutaneous A549 tumors after intravenous injection, outperforming KD3 and wild-type Ad5.
- INGN 007 demonstrated efficacy in a challenging A549 orthotopic lung cancer model and was superior to dl1520 against A549 tumors.
Conclusions:
- INGN 007 exhibits potent oncolytic activity and superior antitumor efficacy compared to KD3, wild-type Ad5, and dl1520 in preclinical models.
- The wild-type E1A gene in INGN 007, combined with ADP overexpression, contributes to enhanced therapeutic potential.
- INGN 007 represents a promising oncolytic adenovirus vector for clinical development in cancer therapy.
